Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area
Biogen is paying around $800m cash to buy UK-based Nightstar Therapeutics, which focuses on gene therapy for retinal diseases.
You may also be interested in...
Japanese company joins the ranks of big pharma buying up gene therapy pioneers
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.